Description

1. Product Overview: Alecnib is a capsule formulation of Alectinib Hydrochloride INN 150 mg, a targeted anticancer agent used in the treatment of ALK-positive non-small cell lung cancer (NSCLC).
2. Composition: Active Ingredient: Alectinib Hydrochloride INN 150 mg | Dosage Form: Capsule
3. Pharmacological Class: ALK (Anaplastic Lymphoma Kinase) Inhibitor
4. Mechanism of Action: Alectinib selectively inhibits ALK tyrosine kinase activity, blocking signaling pathways that promote cancer cell growth and survival, leading to tumor regression.
5. Indications: ALK-positive metastatic or locally advanced non-small cell lung cancer (NSCLC)
6. Dosage & Administration: As prescribed by oncologist | Oral use | Usually taken twice daily with food | Swallow capsules whole
7. Clinical Benefits: Targets ALK-positive cancer cells selectively | Effective in controlling disease progression | Improves progression-free survival | Active in brain metastases
8. Contraindications: Hypersensitivity to Alectinib or any component
9. Precautions: Monitor liver function tests | Risk of interstitial lung disease | Monitor heart rate and muscle symptoms | Use under specialist supervision
10. Drug Interactions: CYP3A inhibitors and inducers may affect drug levels
11. Special Populations: Pregnancy contraindicated | Lactation not recommended | Pediatric safety not established | Use cautiously in hepatic impairment
12. Adverse Effects: Fatigue | Constipation | Edema | Myalgia | Elevated liver enzymes
13. Storage Conditions: Store below 30°C | Protect from light and moisture | Keep out of reach of children
14. Packaging: Capsule in blister pack
15. Manufacturer: Everest Pharmaceutical Ltd.